Triglyceride-lowering therapy for hypertriglyceridemia. Literature review
DOI:
https://doi.org/10.21638/spbu11.2024.202Abstract
Hypertriglyceridemia is a polyetiological lipid metabolism disorder, which is characterized by
an increased residual risk of atherosclerosis-associated cardiovascular system pathology. This
literature review presents current data on aspects of drug therapy for this dyslipidemia, which allows for a more comprehensive approach to the treatment strategies. This analysis is based on modern sources, the materials of which were published from 2010 to 2024 in Russian and English in international scientific online libraries. The article discusses the main drugs groups to consider the phenomenon under consideration: niacin, fibrates, omega-3 polyunsaturated fatty acids. The analysis of research results indicates that the prescription of drugs aimed at reducing triglyceride levels is a promising direction in advanced lipidology. The most promising drugs at the moment are omega-3 polyunsaturated fatty acids, fibric acid agents, and evinacumab. The pharmacological correction features of high triglyceride levels and promising therapeutic directions are highlighted.
Keywords:
hypertriglyceridemia, dyslipidemia, triglycerides, ipidology, statins, fibrates, niacin, omega-3 polyunsaturated fatty acids
Downloads
Download data is not yet available.
References
Литература
Miller M., Stone N. J., Ballantyne C, Bittner V., Criqui M. H., Ginsberg H. N., Goldberg A. C., Howard W. J., Jacobson M. S., Kris-Etherton P. M., Lennie T. A., Levi M., Mazzone T., Pennathur S. American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.Circulation, 2011, vol. 123, pp. 2292–2333. https://doi.org/10.1161/CIR.0b013e3182160726
Willer C. J., Schmidt E. M., Sengupta S., Peloso G. M., Gustafsson S., Kanoni S., Ganna A., Chen J.,Buchkovich M. L., Mora S. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet, 2013, vol. 45, pp. 1274–1283. https://doi.org/10.1038/ng.2797
Varbo A., Benn M., Tybjærg-Hansen A., Nordestgaard B. G. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.Circulation, 2013, vol. 128, pp. 1298–1309. https://doi.org/10.1161/CIRCULATIONAHA.113.003008
Marston N. A., Giugliano R. P., Im K., Silverman M. G., O’Donoghue M. L., Wiviott S. D., Ference B. A., Sabatine M. S. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes. A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation, 2019, vol. 140, pp. 1308–1317. https://doi.org/10.1161/CIRCULATIONAHA.119.041998
Ference B. A., Kastelein J. J. P., Ray K. K., Ginsberg H. N., Chapman M. J., Packard C. J., Laufs U., Oliver-Williams C., Wood A. M., Butterworth A. S., Di Angelantonio E., Danesh J., Nicholls S. J., Bhatt D. L., Sabatine M. S., Catapano A. L. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA, 2019, vol. 321, pp. 364–373. https://doi.org/10.1001/jama.2018.20045
Manson J. E., Cook N. R., Lee I. M., Christen W., Bassuk S. S., Mora S., Gibson H., Albert C. M., Gordon D., Copeland T., D’Agostino D., Friedenberg G., Ridge C., Bubes V., Giovannucci E. L., Willett W. C., Buring J. E. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer.N. Engl. J. Med., 2019, vol. 380, pp. 23–32. https://doi.org/10.1056/NEJMoa1811403
Bhatt D. L., Steg P. G., Miller M., Brinton E. A., Jacobson T. A., Ketchum S. B., Doyle R. T., Juliano R. A., Jiao L., Granowitz C., Tardif J.-C., Ballantyne Ch. M. REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med., 2019, vol. 380, pp. 11–22. https://doi.org/10.1056/NEJMoa1812792
Acharya P., Talahalli R. R. Aging and hyperglycemia intensify dyslipidemia-induced oxidative stress and inflammation in rats: assessment of restorative potentials of ALA and EPA + DHA. Inflammation, 2019, vol. 42, pp. 946–952. https://doi.org/10.1007/s10753-018-0949-6
Xiu Hong Yang, Qian Ming Tu, Li Li, Yong Ping Guo, Nian Song Wang, Hui Min Jin. Triglyceride-lowering therapy for the prevention of cardiovascular events, stroke, and mortality in patients with diabetes: A meta-analysis of randomized controlled trials. Atherosclerosis, 2023, vol. 0021-9150, pp. 117187. https://doi.org/10.1016/j.atherosclerosis.2023.117187
Visseren F. L. J., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., Bäck M., Benetos A., Biffi A., Boavida J.-M., Capodanno D., Cosyns B., Crawford C., Davos C. H., Desormais I., Di Angelantonio E., Franco O. H., Halvorsen S., Hobbs F. D. R., Hollander M., Jankowska E. A., Michal M., Sacco S., Sattar N., Tokgozoglu L., Tonstad S., Tsioufis K. P., van Dis I., van Gelder I. C., Wanner Ch., Williams B. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J., 2021, vol. 42, no. 34,pp. 3227–3337. https://www.doi.org/10.1093/eurheartj/ehab484
Ginsberg H. N., Elam M. B., Lovato L. C., Crouse J. R. 3rd, Leiter L. A., Linz P., Friedewald W. T., Buse J. B., Gerstein H. C., Probstfield J., Grimm R. H., Ismail-Beigi F., Bigger J. T., Goff D. C. Jr., Cushman W. C., Simons-Morton D. G., Byington R. P. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med., 2010, vol. 362, pp. 1563–1574.
Jun M., Foote C., Jicheng L., Neal B., Patel A., Nicholls S. J., Grobbee D. E., Cass A., Chalmers J., Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet,2010, vol. 375, pp. 1875–1884.
Mach F., Baigent C., Catapano A. L., Koskinas K. C., Casula M., Badimon L., Chapman M. J., De Backer G. G., Delgado V., Ference B. A., Graham I. M., Halliday A., Landmesser U., Mihaylova B., Pedersen T. R., Riccardi G., Richter D. J., Sabatine M. S., Taskinen M.-R., Tokgozoglu L., Wiklund O. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J., 2020, vol. 41, no. 1, pp. 111–188. https://www.doi.org/10.1093/eurheartj/ehz455
Kukharchuk V. V., Ezhov M. V., Sergienko I. V., Arabidze G. G., Balakhonova T. V., Gurevich V. S., Zelveyan P. A., Murataliev T. M., Myrzakhmetova G. Sh., Sudzhaeva O. A., Shek A. B., Azizov V. A., Gornyakova N. B., Kachkovsky M. A., Malyshev P. P., Pokrovsky S. N., Sokolov A. A., Sumarokov A. B., Obrezan A. G., Shaposhnik I. I., Antsiferov M. B., Ansheles A. A., Aronov D. M., Akhmedzhanov N. M., Barbarash O. L., Boytsov S. A., Bubnova M. G., Voevoda M. I., Galstyan G. R., Galyavich A. S.,Drapkina O. M., Duplyakov D. V., Eregin S. Ya., Karpov R. S., Karpov Yu. A., Koziolova N. A.,Konovalov G. A., Konstantinov V. O., Kosmacheva E. D., Nedogoda S. V., Oleinikov V. E., Ragino Yu. I., Skibitsky V. V., Smolenskaya O. G., Khalimov Yu. Sh., Chazova I. E., Filippov A. E., Shestakova M. V., Yakushin S. S. Clinical recommendations of the Eurasian Association of Cardiologists (EAC)Evraziiskii kardiologicheskii zhurnal, 2020, no. 2, pp. 6–29. (In Russian)
Oscarsson J., Onnerhag K., Riserus U., Sunden M., Johansson L., Jansson P. A., Moris L., Nilsson P. M.,Eriksson J. W., Lind L. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. J. Clin. Lipidol., 2018, vol. 12, no. 6, pp. 1390–1403.е4. https://doi.org/10.1016/j.jасl.2018.08.003
Preston Mason R. New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr. Atheroscler. Rep., 2019, vol. 21, pp. 2. https://doi.org/10.1007/s11883-019-0762-1
Nicholls S. J., Lincoff A. M., Garcia M., Bash D., Ballantyne Ch. M., Barter Ph. J., Davidson M. H.,Kastelein J. J. P., Koenig W., McGuire D. K., Mozaffarian D., Ridker P. M., Ray K. K., Katona B. G., Himmelmann A., Loss L. E., Rensfeldt M., Lundström T., Agrawal R., Menon V., Wolski K., Nissen S. E. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA, 2020, vol. 324,no. 22, pp. 2268–2280. https://doi.org/10.1001/jama.2020.22258
Boden W. E., Probstfield J. L., Anderson T., Chaitman B. R., Desvignes-Nickens P., Koprowicz K.,McBride R., Teo K., Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med., 2011, vol. 365, pp. 2255–2267.
The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in highrisk patients. N. Engl. J. Med., 2014, vol. 371, pp. 203–212.
Toth P. P., Shah P. K., Lepor N. E. Targeting hypertriglyceridemia to mitigate cardiovascular risk:A review. American Journal of Preventive Cardiology, 2020, vol. 3, no. 2666–6677, pp. 100086. https://doi.org/10.1016/j.ajpc.2020.100086
Aberra T., Peterson E. D., Pagidipati N. J., Mulder H., Wojdyla D. M., Philip S., Granowitz C., Navar A. M.The association between triglycerides and incident cardiovascular disease: What is “optimal”? J. Clin.Lipidol., 2020, vol. 14, no. 4, pp. 438–447.e3.
Kim K. S., Hong S., Han K., Park C. Y. Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels. Metabolism,2022, vol. 137, pp. 155327. https://www.doi.org/10.1016/j.metabol.2022.155327
Kayıkçıoğlu M., Shahbazova S., İbrahimov F., Can L. H. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort. Turk. Kardiyol. Dern. Ars., 2020, vol. 48, no. 4, pp. 359–367. https://www.doi.org/10.5543/tkda.2019.25169
Ahmad Z., Banerjee P., Hamon S., Chan K. C., Bouzelmat A., Sasiela W. J., Pordy R., Mellis S., Dansky H., Gipe D. A., Dunbar R. L. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation, 2019, vol. 140, pp. 470–486. https:// doi.org/10.1161/CIRCULATIONAHA.118.039107
Witztum J. L., Gaudet D., Freedman S. D., Alexander V. J., Digenio A., Williams K. R., Yang Q., Hughes S. G., Geary R. S., Arca M., Stroes E. S. G., Bergeron J., Soran H., Civeira F., Hemphill L., Tsimikas S., Blom D. J., O’Dea L., Bruckert E. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N. Engl. J. Med., 2019, vol. 381, pp. 531–542.
Laufs U., Parhofer K. G., Ginsberg H. N., Hegele R. A. Clinical review on triglycerides. Eur. Heart J.,2020, vol. 41, pp. 99–109.
Guo Y. Y., Li H. X., Zhang Y., He W. H. Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities. Discov. Med., 2019, vol. 27, no. 147, pp. 101–109.
Yamashita S., Masuda D., Matsuzawa Y. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Curr. Atheroscler. Rep.,2020, vol. 22, no. 5. https://doi.org/10.1007/s11883-020-0823-5
Ogawa S. I., Tsunenari Y., Kawai H., Yamazaki H. Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys. Biopharm. Drug Dispos.,2019, vol. 40, no. 1, pp. 12–17.
Pirillo A., Catapano A. L. How to Handle Elevated Triglycerides: Life after PROMINENT. Curr. Atheroscler.Rep., 2023, vol. 25, no. 12, pp. 921–929. https://doi.org/10.1007/s11883-023-01175-2
Das Pradhan A., Glynn R. J., Fruchart J. C., MacFadyen J. G., Zaharris E. S., Everett B. M., Campbell S. E.,Oshima R., Amarenco P., Blom D. J., Brinton E. A., Eckel R. H., Elam M. B., Felicio J. S., Ginsberg H. N., Goudev A., Ishibashi S., Joseph J., Kodama T., Koenig W., Leiter L. A., Lorenzatti A. J., Mankovsky B., Marx N., Nordestgaard B. G., Páll D., Ray K. K., Santos R. D., Soran H., Susekov A., Tendera M., Yokote K.,Paynter N. P., Buring J. E., Libby P., Ridker P. M. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N. Engl. J. Med., 2022, vol. 387, no. 21, pp. 1923–1934. https://doi.org/10.1056/NEJMoa2210645
Downloads
Published
2024-10-15
How to Cite
Shomin, A., Serezhina, E., & Obrezan, A. (2024). Triglyceride-lowering therapy for hypertriglyceridemia. Literature review. Vestnik of Saint Petersburg University. Medicine, 19(2), 118–127. https://doi.org/10.21638/spbu11.2024.202
Issue
Section
Cardiology
License
Articles of "Vestnik of Saint Petersburg University. Medicine" are open access distributed under the terms of the License Agreement with Saint Petersburg State University, which permits to the authors unrestricted distribution and self-archiving free of charge.
